Morgan Stanley Exelixis, Inc. Transaction History

Morgan Stanley

$1.39 Trillion
Q4 2024

A detailed history of Morgan Stanley transactions in Exelixis, Inc. stock. As of the latest transaction made, Morgan Stanley holds 2,752,573 shares of EXEL stock, worth $108 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

2,752,573

Previous 2,132,364 29.09%

Holding current value

$108 Million

Previous $55.3 Million 65.65%

% of portfolio

0.01%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$25.39 - $36.46 $15.7 Million - $22.6 Million	620,209 Added 29.09%	2,752,573 $91.7 Million
Q3 2024 Nov 14, 2024	SELL	$21.96 - $27.6 $3.32 Million - $4.17 Million	-151,073 Reduced 6.62%	2,132,364 $55.3 Million
Q2 2024 Oct 17, 2024	SELL	$20.34 - $23.73 $49 Million - $57.2 Million	-2,410,410 Reduced 51.35%	2,283,437 $51.3 Million
Q2 2024 Aug 14, 2024	SELL	$20.34 - $23.73 $49 Million - $57.2 Million	-2,410,410 Reduced 51.35%	2,283,437 $51.3 Million
Q1 2024 Oct 17, 2024	BUY	$20.17 - $23.93 $48.6 Million - $57.7 Million	2,410,410 Added 105.56%	4,693,847 $111 Million
Q1 2024 Aug 16, 2024	SELL	$20.17 - $23.93 $1.63 Million - $1.94 Million	-80,884 Reduced 1.69%	4,693,847 $111 Million
Q1 2024 May 15, 2024	SELL	$20.17 - $23.93 $1.63 Million - $1.94 Million	-80,884 Reduced 1.69%	4,693,847 $111 Million
Q4 2023 Aug 16, 2024	BUY	$19.25 - $24.13 $48 Million - $60.1 Million	2,491,294 Added 109.1%	4,774,731 $115 Million
Q4 2023 Feb 13, 2024	BUY	$19.25 - $24.13 $31.5 Million - $39.5 Million	1,636,336 Added 52.14%	4,774,731 $115 Million
Q3 2023 Nov 15, 2023	BUY	$19.04 - $22.74 $10.5 Million - $12.5 Million	551,074 Added 21.3%	3,138,395 $68.6 Million
Q2 2023 Aug 14, 2023	BUY	$18.17 - $20.48 $285,105 - $321,351	15,691 Added 0.61%	2,587,321 $49.4 Million
Q1 2023 May 15, 2023	BUY	$16.3 - $19.41 $4.23 Million - $5.04 Million	259,513 Added 11.22%	2,571,630 $49.9 Million
Q4 2022 Feb 14, 2023	BUY	$14.96 - $17.39 $15.1 Million - $17.6 Million	1,009,945 Added 77.56%	2,312,117 $37.1 Million
Q3 2022 Nov 14, 2022	SELL	$15.68 - $22.27 $4.59 Million - $6.52 Million	-292,781 Reduced 18.36%	1,302,172 $20.4 Million
Q2 2022 Oct 27, 2022	BUY	$17.44 - $23.16 $13 Million - $17.2 Million	743,318 Added 87.28%	1,594,953 $33.2 Million
Q2 2022 Aug 15, 2022	BUY	$17.44 - $23.16 $13 Million - $17.2 Million	743,318 Added 87.28%	1,594,953 $33.2 Million
Q1 2022 Oct 27, 2022	SELL	$17.03 - $22.67 $12.7 Million - $16.9 Million	-743,318 Reduced 46.6%	851,635 $19.3 Million
Q1 2022 May 13, 2022	BUY	$17.03 - $22.67 $680,518 - $905,893	39,960 Added 4.92%	851,635 $19.3 Million
Q4 2021 Feb 14, 2022	BUY	$15.84 - $21.88 $456,017 - $629,903	28,789 Added 3.68%	811,675 $14.8 Million
Q3 2021 Nov 15, 2021	BUY	$16.3 - $21.14 $12.8 Million - $16.6 Million	782,886 New	782,886 $16.6 Million

Others Institutions Holding EXEL

# of Institutions

566

Shares Held

251M

Call Options Held

1.45M

Put Options Held

1.13M

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $12.6B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account